AbbVie ABBV is set to report fourth-quarter and full-year 2024 earnings on Jan. 31, before the opening bell. The Zacks ...

Monday was a grim day for a great many stocks, but luckily for its investors, AbbVie (NYSE: ABBV) wasn't one of them. The ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...

AbbVie (ABBV) is one of the stocks most watched ... And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward.

Guggenheim analyst Vamil Divan lowered the firm’s price target on AbbVie (ABBV) to $212 from $221 and keeps a Buy rating on the shares. The ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tim Anderson from Bank of ...

Investors who were hoping for huge dividend increases may want to adjust their expectations. Today, AbbVie's dividend payout ratio is 61% of 2024 earnings. That leaves plenty of room for future ...

AbbVie (ABBV) is one of the stocks most watched ... And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward.

Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie's pipeline and R&D capabilities ...